{"id":127,"date":"2025-09-06T10:03:00","date_gmt":"2025-09-06T10:03:00","guid":{"rendered":"https:\/\/wickedsister.evit.com.au\/index.php\/2025\/09\/06\/neurofilament-the-new-imaging-machine\/"},"modified":"2025-09-06T10:03:00","modified_gmt":"2025-09-06T10:03:00","slug":"neurofilament-the-new-imaging-machine","status":"publish","type":"post","link":"https:\/\/wickedsister.evit.com.au\/index.php\/2025\/09\/06\/neurofilament-the-new-imaging-machine\/","title":{"rendered":"neurofilament the new imaging machine"},"content":{"rendered":"<div class=\"twitter-share\"><a href=\"https:\/\/twitter.com\/intent\/tweet?url=https%3A%2F%2Fmultiple-sclerosis-research.org%2F2025%2F09%2Fneurofilament-the-new-imaging-machine%2F&#038;via=the_MSBlog\" class=\"twitter-share-button\" data-size=\"large\">Tweet<\/a><\/div>\n<p>Neurofilament is a marker of `nerve damage and so can spot sub clinical  attacks, we have been using this for years to help detect active disease. somet;imes lesions cant be seen on MRI, <\/p>\n<p>van Pamelen J, Koel-Simmelink MJA, Lissenberg BI, Arnoldus EPJ, de Beukelaar J, van Vliet J, Killestein J, Teunissen CE, Visser LH. Relapse or no relapse in multiple sclerosis: Can disease activity biomarkers support the clinician? Mult Scler J Exp Transl Clin. 2025 Sep 2;11(3):20552173251370830.<\/p>\n<p><strong>Background:&nbsp;<\/strong>In relapsing-remitting multiple sclerosis (RRMS), the assessment of clinical disease activity can be challenging.<\/p>\n<p><strong>Objectives:&nbsp;<\/strong>To determine the diagnostic potential of serum neurofilament light (sNfL) and glial fibrillary acidic protein (sGFAP) to distinguish a relapse from other causes of deterioration.<\/p>\n<p><strong>Methods:&nbsp;<\/strong>In this multicenter, prospective study, RRMS patients with new neurological symptoms in the last 14 days were followed for 12 weeks. A diagnosis was established by the treating physician or, when in doubt, a panel of experienced neurologists. Blood samples were taken at baseline and week 12.<\/p>\n<p><strong>Results:&nbsp;<\/strong>A total of 65 patients were included. At baseline, patients with a clear relapse had a significantly higher median sNfL (14.6 pg\/mL) than those with a clear other cause (9.5 pg\/mL,&nbsp;<em>p<\/em>&nbsp;= 0.004). Although not significant after correction for multiple testing, median sGFAP was also higher in relapse patients (73.0 vs 64.6 pg\/mL,&nbsp;<em>p<\/em>&nbsp;= 0.036). An sNfL value below 6.0 pg\/mL had a high sensitivity (67% at baseline (CI 22.3-95.7%) and 100% at follow-up (CI 54.1-100%)) to rule out a relapse.<\/p>\n<p><strong>Conclusions:&nbsp;<\/strong>Analysis of sNfL level can be useful as an add-on investigation to determine whether disease activity is present in patients with RRMS presenting with new symptoms.<\/p>\n<p><strong>Keywords:&nbsp;<\/strong>Relapsing-remitting multiple sclerosis; glial fibrillary acidic protein; neurofilament light; pseudo relapse; relapse.<\/p>\n<p><em>Source: <a href=\"https:\/\/multiple-sclerosis-research.org\/2025\/09\/neurofilament-the-new-imaging-machine\/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=neurofilament-the-new-imaging-machine\" rel=\"nofollow noopener\" target=\"_blank\">multiple-sclerosis-research.org<\/a><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Tweet Neurofilament is a marker of `nerve damage and so can spot sub clinical attacks, we have been using this for years to help detect active disease. somet;imes lesions cant be seen on MRI, van Pamelen J, Koel-Simmelink MJA, Lissenberg BI, Arnoldus EPJ, de Beukelaar J, van Vliet J, Killestein J, Teunissen CE, Visser LH&#8230;.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[7,6,5],"class_list":["post-127","post","type-post","status-publish","format-standard","hentry","category-multiple-sclerosis-research","tag-advisories","tag-security","tag-windows"],"_links":{"self":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts\/127","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/comments?post=127"}],"version-history":[{"count":0,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts\/127\/revisions"}],"wp:attachment":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/media?parent=127"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/categories?post=127"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/tags?post=127"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}